UNCY Company Profile and Key Details

UNCY has shown sold momentum, gaining 12.1% over the past week and 39.7% over the past quarter, though year-to-date performance is up 14.04%. Short-term trend indicators are bearishly aligned (SMA20 5.81%, SMA50 9.32%, SMA200 26.43%). The stock’s 14-day RSI is 56.26 (neutral), while the ATR of 0.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.82% below its high and over 84.37% above its low. Average 10-day trading volume of 423.18 thousand shares is below the 3-month average of 503.00 thousand, indicating normal recent market interest.

Unicycive Therapeutics, Inc. has 17.66 million shares outstanding. The public float is 13.01 million shares, elevated short interest at 7.55% of float. This equals 1.28 million shares. The short ratio is 2.79 days. Institutional investors hold 34.9% of the float. Insiders own 2.49%.

Unicycive Therapeutics, Inc. generated EPS of -$3.25 over the past year. Five-year average earnings growth is -31.8%. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.47. Next year's EPS is expected at $66.05. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $15.00. The high target offers 422.19% upside. The low target suggests 95.82% downside. The mean target is $24.50. This offers 219.84% upside. Unicycive Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 30, 2026, missed forecasts by -37.56%. The prior quarter beat by -43.6%. Over the last six quarters, Apple has recorded several small beats. These include -34.78% in August 14, 2024.

Unicycive Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) closed at $7.67 USD, gaining $0.01 (0.13%) from the previous close of $7.66. The stock is currently mid-range between its 52-week high and low $3.71 and $11.00. With a market capitalization of about $164.84 million, Unicycive Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 501.33 thousand shares, in line with its 52-week average. Headquartered in Los Altos, CA, Unicycive Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shalabh K. Gupta, the company employs approximately 22 people and listed since July 12, 2021. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.

Unicycive Therapeutics, Inc. trades at a P/E ratio of -45.89, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 40.35 reflecting a rich premium to book value. The P/FCF stands at -5.26, also above market averages. Compared to sector medians, Unicycive Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Unicycive Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.26%, with price expected at $7.91 by May 14, 2026, within a range of $7.63 to $8.18 3-Month Outlook: Projected fall of -31.72%, reaching $5.23 by July 29, 2026, with a range of $4.90 to $5.52. 1-Year Outlook: Projected gain of 179.11%, with price at $21.38 by April 30, 2027, within a range of $7.01 to $31.93.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares are up 14.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Unicycive Therapeutics, Inc. trading at a premium to the broader market with a P/E of -45.89. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $8.61, suggesting 12.4% upside. Our AI forecast model points to short-term strength (3.26% over two weeks), a medium-term fall (-31.72% over three months), and a longer-term gain (179.11% over one year), with expected trading ranges indicating moderate volatility.